In vitro analytical and antibiotic comparison of generic moxifl oxacin against E. coli and S. aureus bacteria strains

Introduction: Moxifloxacin is a quinolone antibiotic often used to treat infections caused by Gram-positive bacteria that have developed resistance in Colombia in recent years. Objective: To evaluate the concentration of active ingredient and the antibacterial activity of two generic versions versus United States Pharmacopeia (USP) standard of moxifloxacin drugs marketed in Colombia. Methods: This study was designed to evaluate the concentration of the main active ingredient in moxifloxacin antibiotic formulations through high performance liquid chromatography (HPLC), It also determined the antibiotic activity through the minimum inhibitory concentration of generic versions of moxifloxacin and its USP standard equivalent, against strains of Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) bacteria isolated from hospitalized patients of an Intensive Care Unit, American Type Culture Collection (ATCC) bacterial strains that are both sensitive and resistant, and isolates from MICROKIT Laboratories. Results and Discussion: It has been found that the concentrations of the main active ingredient in both generic and standard medications are in the range established by the USP 38, required for the submission of injectable moxifloxacin 400 mg/250 mL. The results for the minimum inhibitory concentration (MIC) of both generics alternative and USP standard of moxifloxacin were 0.125 mu g/mL, 4 mu g/mL, and 8 mu g/mL for resistant S. aureus, ATCC and tropical E. coli bacteria, respectively. Conclusion: Here, both generic products showed similar MIC values on all bacteria evaluated.